Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

236 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
mTOR inhibitors in the treatment of cancer.
Fasolo A, Sessa C. Fasolo A, et al. Expert Opin Investig Drugs. 2008 Nov;17(11):1717-34. doi: 10.1517/13543784.17.11.1717. Expert Opin Investig Drugs. 2008. PMID: 18922108 Review.
Targeting mTOR pathways in human malignancies.
Fasolo A, Sessa C. Fasolo A, et al. Curr Pharm Des. 2012;18(19):2766-77. doi: 10.2174/138161212800626210. Curr Pharm Des. 2012. PMID: 22475451 Review.
Clinical and pharmacological phase I evaluation of Exherin (ADH-1), a selective anti-N-cadherin peptide in patients with N-cadherin-expressing solid tumours.
Perotti A, Sessa C, Mancuso A, Noberasco C, Cresta S, Locatelli A, Carcangiu ML, Passera K, Braghetti A, Scaramuzza D, Zanaboni F, Fasolo A, Capri G, Miani M, Peters WP, Gianni L. Perotti A, et al. Among authors: fasolo a. Ann Oncol. 2009 Apr;20(4):741-5. doi: 10.1093/annonc/mdn695. Epub 2009 Feb 3. Ann Oncol. 2009. PMID: 19190075 Free article. Clinical Trial.
A phase Ib dose-escalation study of the MEK inhibitor trametinib in combination with the PI3K/mTOR inhibitor GSK2126458 in patients with advanced solid tumors.
Grilley-Olson JE, Bedard PL, Fasolo A, Cornfeld M, Cartee L, Razak AR, Stayner LA, Wu Y, Greenwood R, Singh R, Lee CB, Bendell J, Burris HA, Del Conte G, Sessa C, Infante JR. Grilley-Olson JE, et al. Among authors: fasolo a. Invest New Drugs. 2016 Dec;34(6):740-749. doi: 10.1007/s10637-016-0377-0. Epub 2016 Jul 23. Invest New Drugs. 2016. PMID: 27450049 Free PMC article. Clinical Trial.
Translational research in phase I trials.
Fasolo A, Sessa C. Fasolo A, et al. Clin Transl Oncol. 2009 Sep;11(9):580-8. doi: 10.1007/s12094-009-0408-9. Clin Transl Oncol. 2009. PMID: 19775997 Review.
Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F, Hurvitz S, Fasolo A, Tseng LM, Jerusalem G, Wilks S, O'Regan R, Isaacs C, Toi M, Burris H, He W, Robinson D, Riester M, Taran T, Chen D, Slamon D. André F, et al. Among authors: fasolo a. J Clin Oncol. 2016 Jun 20;34(18):2115-24. doi: 10.1200/JCO.2015.63.9161. Epub 2016 Apr 18. J Clin Oncol. 2016. PMID: 27091708 Clinical Trial.
236 results